Lyudmila Dzyak

Lyudmila Dzyak

Auto-generated profile, based on publicly available information

Lyudmila Dzyak

Dnipro State Medical University, Dnipro, Ukraine

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2016 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
WPWerner Poewe
Werner Poewe
PBPierre Burbaud
Pierre Burbaud
GCGiovanni Castelnovo
Giovanni Castelnovo
WJWolfgang H. Jost
Wolfgang H. Jost
ACAndres O. Ceballos‐Baumann
Andres O. Ceballos‐Baumann
PPPhilippe Picaut
Philippe Picaut

17 April 2015 in CNS Drugs
Verified
Journal Article
Open access
PDF file
CWCheryl H. Waters
Cheryl H. Waters
PNPaul Nausieda
Paul Nausieda
LDLyudmila Dzyak
Lyudmila Dzyak
JSJoerg Spiegel
Joerg Spiegel
MRMonika Rudzińska-Bar
Monika Rudzińska-Bar
SGSuneel Gupta
Suneel Gupta
Background and Objective IPX066 is a multiparticulate extended-release formulation of carbidopa–levodopa, designed to produce prolonged therapeutic levodopa plasma concentrations. This 9-month open-label extension study assessed its long-term safety and clinical utility in early and advanced Parkinson’s disease (PD). Methods Participants were enrolled from two phase III IPX066 studies and one open-label phase II study. Early PD patients were titrated to an appropriate dosing regimen while advanced patients started with regimens established in the antecedent studies. Adjustment was allowed throughout the extension. Clinical utility measures included the Unified Parkinson’s Disease Rating Scale (UPDRS) and Patient Global Impression (PGI) ratings. Results Among 268 early PD patients, 53.4 % reported adverse events (AEs) and 1.1 % (three patients) discontinued due to AEs; the most frequent AEs were nausea (5.6 %) and insomnia (5.6 %). Among 349 advanced patients, 60.2 % reported AEs and 3.7 % (13 patients) discontinued due to AEs; the most frequent AEs were dyskinesia (6.9 %) and fall (6.6 %). At month 9 (or early termination), 78.3 % of early patients were taking IPX066 three times daily (median: 720 mg/day) and 87.7 % of advanced patients were taking IPX066 three or four times daily (median: 1450 mg/day). Adjusting for 70 % bioavailability relative to immediate-release (IR) carbidopa–levodopa, the median dosages correspond to ~500 and ~1015 mg/day of IR levodopa in early and advanced PD, respectively. Based on the plasma profiles previously observed in PD patients, the IPX066 regimens in the extension can be estimated to provide a levodopa C max (maximum plasma drug concentration) similar to or lower than that provided by IR regimens during the antecedent trials. UPDRS and PGI findings showed sustained treatment effects throughout the extension. Conclusion During 9 months of extended use, IPX066 exhibited a safety/tolerability profile consistent with dopaminergic PD therapy.

15 May 2015 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
MSM. Salkov
M. Salkov
VTV. Tsymbaliuk
V. Tsymbaliuk
LDL. Dzyak
L. Dzyak
ARA. Rodinsky
A. Rodinsky
YCY. Cherednichenko
Y. Cherednichenko
GTG. Titov
G. Titov

1 July 1999 in Neurophysiology
Verified
Journal Article
Closed access
PDF file
LDL. A. Dzyak
L. A. Dzyak
TDT. I. Duka
T. I. Duka
ADA. L. Drozdov
A. L. Drozdov
VCV. I. Chernaya
V. I. Chernaya

9 April 2020 in Medicni perspektivi
Verified
Journal Article
Open access
PDF file
LDL. A. Dzyak
L. A. Dzyak
OSO. O. Shulga
O. O. Shulga
Concept of a complex therapy in restorative treatment of discogenic lumbosacral radiculopathies.

20 September 2002 in Biopolymers and Cell
Verified
Journal Article
Open access
ADA. L. Drozdov
A. L. Drozdov
LDL. A. Dzyak
L. A. Dzyak
VCV. I. Chornaya
V. I. Chornaya